3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates involves navigating volatility and inherent risks [1] Group 1: Company Overview - Idexx Laboratories (IDXX) is highlighted as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company operates in the animal diagnostic and health care sector, which is currently experiencing strong growth potential [3] Group 2: Earnings Growth - Idexx has a historical EPS growth rate of 11.4%, with projected EPS growth of 17.6% for the current year, surpassing the industry average of 14.8% [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Idexx is currently at 6%, significantly higher than the industry average of -2.5% [5] - Over the past 3-5 years, Idexx has maintained an annualized cash flow growth rate of 14.6%, compared to the industry average of 6.3% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Idexx have been revised upward, with the Zacks Consensus Estimate increasing by 3.3% over the past month [8] Group 5: Investment Potential - Idexx has achieved a Growth Score of B and a Zacks Rank of 2, indicating its potential as an outperformer and a solid choice for growth investors [9][10]